- Home
- CLBR vs MGNX Comparison
CLBR vs MGNX Comparison
Compare CLBR & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLBR
- MGNX
- Stock Information
- Founded
- CLBR 2023
- MGNX 2000
- Country
- CLBR United States
- MGNX United States
- Employees
- CLBR N/A
- MGNX N/A
- Industry
- CLBR
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- CLBR
- MGNX Health Care
- Exchange
- CLBR Nasdaq
- MGNX Nasdaq
- Market Cap
- CLBR 230.6M
- MGNX 257.3M
- IPO Year
- CLBR 2023
- MGNX 2013
- Fundamental
- Price
- CLBR $11.10
- MGNX $3.00
- Analyst Decision
- CLBR
- MGNX Hold
- Analyst Count
- CLBR 0
- MGNX 10
- Target Price
- CLBR N/A
- MGNX $7.17
- AVG Volume (30 Days)
- CLBR 403.7K
- MGNX 496.5K
- Earning Date
- CLBR 01-01-0001
- MGNX 03-06-2025
- Dividend Yield
- CLBR N/A
- MGNX N/A
- EPS Growth
- CLBR N/A
- MGNX N/A
- EPS
- CLBR N/A
- MGNX N/A
- Revenue
- CLBR N/A
- MGNX $141,329,000.00
- Revenue This Year
- CLBR N/A
- MGNX $174.73
- Revenue Next Year
- CLBR N/A
- MGNX N/A
- P/E Ratio
- CLBR $142.27
- MGNX N/A
- Revenue Growth
- CLBR N/A
- MGNX 16.68
- 52 Week Low
- CLBR $10.05
- MGNX $2.95
- 52 Week High
- CLBR $12.28
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- CLBR 45.83
- MGNX 37.54
- Support Level
- CLBR $10.73
- MGNX $3.00
- Resistance Level
- CLBR $11.34
- MGNX $3.22
- Average True Range (ATR)
- CLBR 0.37
- MGNX 0.17
- MACD
- CLBR -0.08
- MGNX -0.02
- Stochastic Oscillator
- CLBR 32.33
- MGNX 7.69
About CLBR Colombier Acquisition Corp. II
Colombier Acquisition Corp II is a blank check company.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).